Kadmon to present interim data on KD025 in cGVHD at R&D day
Kadmon Holdings will present interim data from its ongoing Phase 2 clinical trial of KD025, the company's lead ROCK2 inhibitor, in previously treated patients with chronic graft-versus-host disease. The data will be presented at Kadmon's Research and Development Day in New York City on Tuesday, July 11, 2017, from 8:45 a.m. to 11:00 a.m. ET. The R&D Day will feature presentations by key opinion leaders, including Bruce Blazar, M.D., Regents Professor in the Department of Pediatrics, Chief of the Pediatric Blood and Marrow Transplantation Program and Vice Dean for Clinical Investigation at the School of Medicine at the University of Minnesota, Minneapolis, MN. Dr. Blazar will share the findings of his preclinical research on KD025 in cGVHD. Also presenting is Amandeep Salhotra, M.D., Assistant Professor, Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, CA. Dr. Salhotra will present interim data from the first cohort of the ongoing cGVHD trial. Kadmon's executive management team, led by Harlan W. Waksal, M.D., President and Chief Executive Officer, will provide an update on KD025 as well as the Company's ROCK inhibitor platform. KD025 is being studied in three ongoing clinical trials in autoimmune and fibrotic diseases: A placebo-controlled Phase 2 clinical trial in moderate to severe psoriasis, an open-label Phase 2 clinical trial in idiopathic pulmonary fibrosis and an open-label Phase 2 clinical trial in cGVHD.